Treating anaplastic thyroid carcinoma with an oncolytic adenovirus

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Reichert-Eberhardt, Aliana
dc.contributor.author Reddi, Honey V.
dc.contributor.author Copland, John A.
dc.contributor.author Galanis, Evanthia
dc.contributor.author McIver, Bryan
dc.contributor.author Grebe, Stefan K.G.
dc.contributor.author Eberhardt, Norman L.
dc.date.accessioned 2007-06-01T15:51:41Z
dc.date.available 2007-06-01T15:51:41Z
dc.date.issued 2007-06-01T15:51:41Z
dc.identifier.uri http://hdl.handle.net/2092/578
dc.description.abstract Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer. Standard therapy is rarely curative, and the tumors are resistant to radioiodine or chemotherapy. Oncolytic viruses may be used to treat ATC. ONYX-015, a modified adenovirus designed to replicate preferentially in p53-mutated cells, induces apoptosis in p53 defective ATC cell lines. However, this effect is not entirely specific to p53 deficient cells, inducing apoptosis in some normal cells. This toxicity limits ONYX-015 to topical use. ONYX-411 is a related oncolytic virus that replicates in cells with impaired function of the retinoblastoma protein (pRB) pathway. This virus exhibits higher selectivity for malignant cells, making it potentially suitable for systemic therapy. This study demonstrates the efficacy of ONYX-411 to inhibit cell growth of the ATC cell lines ARO, DRO, and BHT101, and compares its tumoricidal effects with those of ONYX-015 (1) and PPAR gamma agonist (2) treatment. Quantitation of cell death was achieved by a cell viability assay (MTT). A thyroid cell line immortalized with SV40 large T-antigen (NThy-ori3-1), which inactivates both p53 and pRb, was the positive control. Short-term cultured primary thyrocytes served as a negative control. These in vitro studies showed that ONYX-411 was most effective in BHT101, achieving 80% cell death within 72 hours at an moi of 25. This effect was less prominent in ARO and DRO cells, and the degree of cell killing correlated with the extent of pRB dysfunction quantitated by western blot. Further, unlike ONYX-015, ONYX-411 was non-toxic to normal thyrocytes. en
dc.description.sponsorship Mayo Clinic, Rochester MN en
dc.format.extent 2503631 bytes
dc.format.mimetype application/pdf
dc.language.iso en_US
dc.relation.ispartofseries DUCURS 2006;37
dc.subject Anaplastic thyroid carcinoma en
dc.subject Cancer en
dc.subject Oncolytic adenovirus en
dc.subject Thyroid gland -- Cancer en
dc.subject Thyroid gland -- Cancer -- Treatment en
dc.title Treating anaplastic thyroid carcinoma with an oncolytic adenovirus en
dc.type Presentation en


Files in this item

This item appears in the following Collection(s)

  • DUCURS [193]
    Poster sessions and presentation from the Drake University Conference on Undergraduate Research in the Sciences held each April at Olmsted Center on the Drake campus.

Show simple item record

Search DSpace


Advanced Search

Browse

My Account